Berkeley Lights presents its optofluidic discovery

EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation in the upcoming Festival of Biologics meeting, which will will be held from March 9 – December 11, 2022, at the Marriott Marquis San Diego. The Festival of Biologics brings together pharmaceutical, biotechnology, academic and research institutes and their partners across the value chain in the fields of antibodies, immunotherapy and biosimilars.

Berkeley Lights will demonstrate the Berkeley Lights Platform and Single B-Cell Antibody Discovery Workflow at Booth #39. Meeting attendees visiting the Berkeley Lights booth can receive a demonstration of the Beacon System running the workflow Opto™ Plasma B Discovery Workflow and learn more about the Opto™ Cell Line Development Workflow.

Presentation
Mr. Kent Lee, Antibody Discovery Product Manager at Berkeley Lights, will be presenting titled “Leave No Hit Behind: Accelerating the Discovery of Lead Molecules Against Difficult Targets”, Thursday, March 10 from 12:40 p.m. to 1 p.m. PT. In this presentation, Lee will explain how Berkeley Lights’ Beacon Optofluidic System is used to rapidly discover antibodies against difficult targets, such as GPCRs, compared to traditional hybridoma methods.

About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights platform captures in-depth phenotypic, functional and genotypic information for thousands of individual cells in parallel and can also deliver the live biology customers want in the form of the best cells. Our platform is a fully integrated end-to-end solution, featuring proprietary consumables including our OptoSelect™ chips and reagent kits, advanced automation systems and application software. We have developed the Berkeley Lights platform to provide the most advanced environment for the rapid functional characterization of large-scale single cells, which aims to set an industry standard for our customers throughout their supply chain. value of cell-based products.

Berkeley Lights Lighthouse® and the Lightning™ Systems and Culture Station™ Instrument are FOR RESEARCH PURPOSES ONLY. Not for use in diagnostic procedures.

Forward-looking statements
To the extent that the statements in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting management’s current beliefs and expectations. These forward-looking statements involve substantial known and unknown risks and uncertainties relating to future events, and actual results and product performance could differ materially from those expressed or implied by the forward-looking statements. Berkeley Lights assumes no obligation to update or revise any forward-looking statements. For a more detailed description of the risks and uncertainties associated with the growth and continued development of the Company, see the statements in the “Risk Factors” sections, and elsewhere, in our filings with the Securities and Exchange Commission. United States.

Media Contacts
[email protected]

Contact Investor
[email protected]

Comments are closed.